We'll said - we all know AMBS has strong muscle in their pipe. Capitalizing on it is a treacherous landscape to maneuver. BP's intuitively understand this vulnerability and like vulchers, are always on the hunt for cash strapped young OTC's caught in the grip of illiquidity. Point being - GC's salary increase, addit. 5-Mil share increase and $120k target bonus would have been much bettered timed and better received by the market had it been predicated on revenue generation - as without accomplishing such, these items just add to an already elongated paper runway. AMBS credit lines with Iron Ridge, Infusion, Dominion and LPC will mature and the all these 'calls' will be paid one - way or another. Until revenue is recognized, our leverage will remain more and more encumbered.